{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:18:24Z","timestamp":1793038704745,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurodegenerative diseases (NDs) are an accelerating global health problem. Nevertheless, the stronghold of the brain- the blood\u2013brain barrier (BBB) prevents drug penetrance and dwindles effective treatments. Therefore, it is crucial to identify Trojan horse-like drug carriers that can effectively cross the blood\u2013brain barrier and reach the brain tissue. We have previously developed polyunsaturated fatty acids (PUFA)-based nanostructured lipid carriers (NLC), namely DHAH-NLC. These carriers are modulated with BBB-permeating compounds such as chitosan (CS) and trans-activating transcriptional activator (TAT) from HIV-1 that can entrap neurotrophic factors (NTF) serving as nanocarriers for NDs treatment. Moreover, microglia are suggested as a key causative factor of the undergoing neuroinflammation of NDs. In this work, we used in vitro models to investigate whether DHAH-NLCs can enter the brain via the BBB and investigate the therapeutic effect of NTF-containing DHAH-NLC and DHAH-NLC itself on lipopolysaccharide-challenged microglia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We employed human induced pluripotent stem cell-derived brain microvascular endothelial cells (BMECs) to capitalize on the in vivo-like TEER of this BBB model and quantitatively assessed the permeability of DHAH-NLCs. We also used the HMC3 microglia cell line to assess the therapeutic effect of NTF-containing DHAH-NLC upon LPS challenge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      TAT-functionalized DHAH-NLCs successfully crossed the in vitro BBB model, which exhibited high transendothelial electrical resistance (TEER) values (\u22483000 \u03a9*cm\n                      <jats:sup>2<\/jats:sup>\n                      ). Specifically, the TAT-functionalized DHAH-NLCs showed a permeability of up to 0.4% of the dose. Furthermore, using human microglia (HMC3), we demonstrate that DHAH-NLCs successfully counteracted the inflammatory response in our cultures after LPS challenge. Moreover, the encapsulation of glial cell-derived neurotrophic factor (GNDF)-containing DHAH-NLCs (DHAH-NLC-GNDF) activated the Nrf2\/HO-1 pathway, suggesting the triggering of the endogenous anti-oxidative system present in microglia\n                      <jats:bold>.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, this work shows that the TAT-functionalized DHAH-NLCs can cross the BBB, modulate immune responses, and serve as cargo carriers for growth factors; thus, constituting an attractive and promising novel drug delivery approach for the transport of therapeutics through the BBB into the brain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12987-022-00315-1","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T01:02:48Z","timestamp":1647478968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Dual effect of TAT functionalized DHAH lipid nanoparticles with neurotrophic factors in human BBB and microglia cultures"],"prefix":"10.1186","volume":"19","author":[{"given":"Sara","family":"Hernando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyxeni","family":"Nikolakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Voulgaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoli","family":"Igartua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Herland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"issue":"2","key":"315_CR1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","volume":"57","author":"BV Zlokovic","year":"2008","unstructured":"Zlokovic BV. The blood\u2013brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178\u2013201.","journal-title":"Neuron"},{"issue":"12","key":"315_CR2","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nm.3407","volume":"19","author":"B Obermeier","year":"2013","unstructured":"Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19(12):1584\u201396.","journal-title":"Nat Med"},{"issue":"3","key":"315_CR3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood\u2013brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133\u201350.","journal-title":"Nat Rev Neurol"},{"key":"315_CR4","unstructured":"Neurological Disorders: Public Health Challenges. https:\/\/www.who.int\/mental_health\/neurology\/neurodiso\/en\/. Accessed 10 May 2021"},{"key":"315_CR5","unstructured":"World Alzheimer Report 2019: Attitudes to dementia. https:\/\/www.alz.co.uk\/research\/world-report-2019. Accessed 10 May 2021"},{"key":"315_CR6","doi-asserted-by":"crossref","DOI":"10.1038\/s41531-018-0058-0","volume":"4","author":"C Marras","year":"2018","unstructured":"Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, Abbott RD, Savica R, Van Den Eeden SK, Willis AW, Tanner CM, Parkinson\u2019s Foundation P4 Group. Prevalence of Parkinson\u2019s disease across North America. NPJ Parkinsons Dis. 2018;4: 21-018-0058-0 (eCollection 2018).","journal-title":"NPJ Parkinsons Dis"},{"issue":"3","key":"315_CR7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","volume":"16","author":"R Briggs","year":"2016","unstructured":"Briggs R, Kennelly SP, O\u2019Neill D. Drug treatments in Alzheimer\u2019s disease. Clin Med (Lond). 2016;16(3):247\u201353.","journal-title":"Clin Med (Lond)"},{"issue":"Suppl 1","key":"315_CR8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jnc.13750","volume":"139","author":"W Oertel","year":"2016","unstructured":"Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem. 2016;139(Suppl 1):325\u201337.","journal-title":"J Neurochem"},{"issue":"10","key":"315_CR9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Y Hou","year":"2019","unstructured":"Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15(10):565\u201381.","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"315_CR10","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41593-018-0237-7","volume":"21","author":"L Gan","year":"2018","unstructured":"Gan L, Cookson MR, Petrucelli L, La Spada AR. Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci. 2018;21(10):1300\u20139.","journal-title":"Nat Neurosci"},{"issue":"5","key":"315_CR11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1242\/dmm.030205","volume":"10","author":"AD Gitler","year":"2017","unstructured":"Gitler AD, Dhillon P, Shorter J. Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech. 2017;10(5):499\u2013502.","journal-title":"Dis Model Mech"},{"issue":"2","key":"315_CR12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11481-014-9534-4","volume":"9","author":"S Buch","year":"2014","unstructured":"Buch S. Growth factor signaling: implications for disease and therapeutics. J Neuroimmune Pharmacol. 2014;9(2):65\u20138.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"11","key":"315_CR13","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2174\/1567205014666170329113007","volume":"14","author":"V Echeverria","year":"2017","unstructured":"Echeverria V, Barreto GE, Avila-Rodriguezc M, Tarasov VV, Aliev G. Is VEGF a key target of cotinine and other potential therapies against Alzheimer disease? Curr Alzheimer Res. 2017;14(11):1155\u201363.","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"315_CR14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cytogfr.2011.05.001","volume":"22","author":"AM Sullivan","year":"2011","unstructured":"Sullivan AM, Toulouse A. Neurotrophic factors for the treatment of Parkinson\u2019s disease. Cytokine Growth Factor Rev. 2011;22(3):157\u201365.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"315_CR15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","volume":"138","author":"SJ Allen","year":"2013","unstructured":"Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther. 2013;138(2):155\u201375.","journal-title":"Pharmacol Ther"},{"key":"315_CR16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.plefa.2017.03.006","volume":"136","author":"GY Sun","year":"2018","unstructured":"Sun GY, Simonyi A, Fritsche KL, Chuang DY, Hannink M, Gu Z, Greenlief CM, Yao JK, Lee JC, Beversdorf DQ. Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases. Prostaglandins Leukot Essent Fatty Acids. 2018;136:3\u201313.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"315_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174256","author":"R Avallone","year":"2019","unstructured":"Avallone R, Vitale G, Bertolotti M. Omega-3 fatty acids and neurodegenerative diseases: new evidence in clinical trials. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20174256.","journal-title":"Int J Mol Sci"},{"key":"315_CR18","first-page":"1","volume":"3","author":"P Li","year":"2020","unstructured":"Li P, Song C. Potential treatment of Parkinson\u2019s disease with omega-3 polyunsaturated fatty acids. Nutr Neurosci. 2020;3:1\u201312.","journal-title":"Nutr Neurosci"},{"issue":"36","key":"315_CR19","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.2174\/0929867321666140815124246","volume":"21","author":"E Garbayo","year":"2014","unstructured":"Garbayo E, Estella-Hermoso de Mendoza A, Blanco-Prieto MJ. Diagnostic and therapeutic uses of nanomaterials in the brain. Curr Med Chem. 2014;21(36):4100\u201331.","journal-title":"Curr Med Chem"},{"issue":"10","key":"315_CR20","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2217\/nnm-2016-0019","volume":"11","author":"S Hernando","year":"2016","unstructured":"Hernando S, Gartziandia O, Herran E, Pedraz JL, Igartua M, Hernandez RM. Advances in nanomedicine for the treatment of Alzheimer\u2019s and Parkinson\u2019s diseases. Nanomedicine (Lond). 2016;11(10):1267\u201385.","journal-title":"Nanomedicine (Lond)"},{"key":"315_CR21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-319-57696-1_3","volume-title":"Drug and Gene Delivery to the Central Nervous System for Neuroprotection","author":"S Hernando","year":"2017","unstructured":"Hernando S, Herran E, Pedraz JL, Igartua M, Hernandez RM, et al. Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment. In: Sharma HS, et al., editors. Drug and Gene Delivery to the Central Nervous System for Neuroprotection. Switzerland: Springer International Publishing; 2017. p. 57\u201387."},{"key":"315_CR22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","volume":"103","author":"A Khosa","year":"2018","unstructured":"Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018;103:598\u2013613.","journal-title":"Biomed Pharmacother"},{"key":"315_CR23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejpb.2020.01.005","volume":"149","author":"M In\u00eas Teixeira","year":"2020","unstructured":"In\u00eas Teixeira M, Lopes CM, Helena Amaral M, Costa PC. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. Eur J Pharm Biopharm. 2020;149:192\u2013217.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"315_CR24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","volume":"12","author":"A Beloqui","year":"2016","unstructured":"Beloqui A, Solin\u00eds M\u00c1, Rodr\u00edguez-Gasc\u00f3n A, Almeida AJ, Pr\u00e9at V. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomed Nanotechnol Biol Med. 2016;12(1):143\u201361.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"4","key":"315_CR25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3797\/scipharm.1105-09","volume":"79","author":"BK Nanjwade","year":"2011","unstructured":"Nanjwade BK, Patel DJ, Udhani RA, Manvi FV. Functions of lipids for enhancement of oral bioavailability of poorly water-soluble drugs. Sci Pharm. 2011;79(4):705\u201327.","journal-title":"Sci Pharm"},{"key":"315_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1166\/jbn.2016.2313","volume":"12","author":"O Gartziandia","year":"2016","unstructured":"Gartziandia O, Herr\u00e1n E, Ruiz-Ortega JA, Miguelez C, Igartua M, Lafuente JV, Pedraz JL, Ugedo L, Hern\u00e1ndez RM. Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson\u00b4s disease. J Biomed Nanotechnol. 2016;12:1\u201311.","journal-title":"J Biomed Nanotechnol"},{"issue":"1","key":"315_CR27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12035-017-0728-7","volume":"55","author":"S Hernando","year":"2018","unstructured":"Hernando S, Herran E, Figueiro-Silva J, Pedraz JL, Igartua M, Carro E, Hernandez RM. Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson\u2019s disease. Mol Neurobiol. 2018;55(1):145\u201355.","journal-title":"Mol Neurobiol"},{"key":"315_CR28","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.colsurfb.2015.06.054","volume":"134","author":"O Gartziandia","year":"2015","unstructured":"Gartziandia O, Herran E, Pedraz JL, Carro E, Igartua M, Hernandez RM. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surf B Biointerfaces. 2015;134:304\u201313.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"1","key":"315_CR29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2010.09.007","volume":"401","author":"Y Agrawal","year":"2010","unstructured":"Agrawal Y, Petkar KC, Sawant KK. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm. 2010;401(1):93\u2013102.","journal-title":"Int J Pharm"},{"key":"315_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12050429","author":"A Huguet-Casquero","year":"2020","unstructured":"Huguet-Casquero A, Moreno-Sastre M, Lopez-Mendez TB, Gainza E, Pedraz JL. Encapsulation of oleuropein in nanostructured lipid carriers: biocompatibility and antioxidant efficacy in lung epithelial cells. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12050429.","journal-title":"Pharmaceutics"},{"issue":"1","key":"315_CR31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijpharm.2013.12.006","volume":"461","author":"LM Negi","year":"2014","unstructured":"Negi LM, Jaggi M, Talegaonkar S. Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers. Int J Pharm. 2014;461(1):403\u201310.","journal-title":"Int J Pharm"},{"key":"315_CR32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.mam.2017.12.004","volume":"64","author":"RJS Lacombe","year":"2018","unstructured":"Lacombe RJS, Chouinard-Watkins R, Bazinet RP. Brain docosahexaenoic acid uptake and metabolism. Mol Aspects Med. 2018;64:109\u201334.","journal-title":"Mol Aspects Med"},{"key":"315_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12100928","author":"S Hernando","year":"2020","unstructured":"Hernando S, Herran E, Hernandez RM, Igartua M. Nanostructured lipid carriers made of omega-3 polyunsaturated fatty acids: in vitro evaluation of emerging nanocarriers to treat neurodegenerative diseases. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12100928.","journal-title":"Pharmaceutics"},{"key":"315_CR34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2018.10.004","volume":"291","author":"AR Khan","year":"2018","unstructured":"Khan AR, Yang X, Fu M, Zhai G. Recent progress of drug nanoformulations targeting to brain. J Control Release. 2018;291:37\u201364.","journal-title":"J Control Release"},{"key":"315_CR35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2016.03.020","volume":"229","author":"D Zhang","year":"2016","unstructured":"Zhang D, Wang J, Xu D. Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems. J Control Release. 2016;229:130\u20139.","journal-title":"J Control Release"},{"issue":"3","key":"315_CR36","first-page":"780","volume":"44","author":"D Singh","year":"2016","unstructured":"Singh D, Kapahi H, Rashid M, Prakash A, Majeed AB, Mishra N. Recent prospective of surface engineered Nanoparticles in the management of neurodegenerative disorders. Artif Cells Nanomed Biotechnol. 2016;44(3):780\u201391.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"12","key":"315_CR37","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/stem.2908","volume":"36","author":"L Delsing","year":"2018","unstructured":"Delsing L, Donnes P, Sanchez J, Clausen M, Voulgaris D, Falk A, Herland A, Brolen G, Zetterberg H, Hicks R, Synnergren J. Barrier properties and transcriptome expression in human iPSC-derived models of the blood\u2013brain barrier. Stem Cells. 2018;36(12):1816\u201327.","journal-title":"Stem Cells"},{"issue":"11","key":"315_CR38","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1093\/brain\/awaa268","volume":"143","author":"P Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou P, Rauti R, Voulgaris D, Shlomy I, Maoz BM, Herland A. Recent progress in translational engineered in vitro models of the central nervous system. Brain. 2020;143(11):3181\u2013213.","journal-title":"Brain"},{"issue":"5","key":"315_CR39","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/0271678X16630991","volume":"36","author":"HC Helms","year":"2016","unstructured":"Helms HC, Abbott NJ, Burek M, Cecchelli R, Couraud PO, Deli MA, Forster C, Galla HJ, Romero IA, Shusta EV, Stebbins MJ, Vandenhaute E, Weksler B, Brodin B. In vitro models of the blood\u2013brain barrier: an overview of commonly used brain endothelial cell culture models and guidelines for their use. J Cereb Blood Flow Metab. 2016;36(5):862\u201390.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"45","key":"315_CR40","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.2174\/1381612825666190220161254","volume":"24","author":"B Miccoli","year":"2018","unstructured":"Miccoli B, Braeken D, Li YE. Brain-on-a-chip devices for drug screening and disease modeling applications. Curr Pharm Des. 2018;24(45):5419\u201336.","journal-title":"Curr Pharm Des"},{"key":"315_CR41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.arr.2016.01.006","volume":"26","author":"FG De Felice","year":"2016","unstructured":"De Felice FG, Munoz DP. Opportunities and challenges in developing relevant animal models for Alzheimer\u2019s disease. Ageing Res Rev. 2016;26:112\u20134.","journal-title":"Ageing Res Rev"},{"issue":"12","key":"315_CR42","doi-asserted-by":"crossref","first-page":"8489","DOI":"10.1007\/s12035-019-01653-2","volume":"56","author":"MA Mofazzal Jahromi","year":"2019","unstructured":"Mofazzal Jahromi MA, Abdoli A, Rahmanian M, Bardania H, Bayandori M, Moosavi Basri SM, Kalbasi A, Aref AR, Karimi M, Hamblin MR. Microfluidic brain-on-a-chip: perspectives for mimicking neural system disorders. Mol Neurobiol. 2019;56(12):8489\u2013512.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"315_CR43","first-page":"272","volume":"33","author":"U Marx","year":"2016","unstructured":"Marx U, Andersson TB, Bahinski A, Beilmann M, Beken S, Cassee FR, Cirit M, Daneshian M, Fitzpatrick S, Frey O, Gaertner C, Giese C, Griffith L, Hartung T, Heringa MB, Hoeng J, de Jong WH, Kojima H, Kuehnl J, Leist M, Luch A, Maschmeyer I, Sakharov D, Sips AJ, Steger-Hartmann T, Tagle DA, Tonevitsky A, Tralau T, Tsyb S, van de Stolpe A, Vandebriel R, Vulto P, Wang J, Wiest J, Rodenburg M, Roth A. Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. Altex. 2016;33(3):272\u2013321.","journal-title":"Altex"},{"issue":"Suppl 2","key":"315_CR44","first-page":"S101","volume":"64","author":"CW Olanow","year":"2008","unstructured":"Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson\u2019s disease? Ann Neurol. 2008;64(Suppl 2):S101\u201310.","journal-title":"Ann Neurol"},{"issue":"3","key":"315_CR45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","volume":"275","author":"LS Schneider","year":"2014","unstructured":"Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M. Clinical trials and late-stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275(3):251\u201383.","journal-title":"J Intern Med"},{"issue":"1","key":"315_CR46","doi-asserted-by":"crossref","DOI":"10.1186\/s12987-020-00191-7","volume":"17","author":"MJ Workman","year":"2020","unstructured":"Workman MJ, Svendsen CN. Recent advances in human iPSC-derived models of the blood\u2013brain barrier. Fluids Barriers CNS. 2020;17(1): 30-020-00191-7.","journal-title":"Fluids Barriers CNS"},{"issue":"6","key":"315_CR47","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.stemcr.2019.05.008","volume":"12","author":"EH Neal","year":"2019","unstructured":"Neal EH, Marinelli NA, Shi Y, McClatchey PM, Balotin KM, Gullett DR, Hagerla KA, Bowman AB, Ess KC, Wikswo JP, Lippmann ES. A simplified, fully defined differentiation scheme for producing blood\u2013brain barrier endothelial cells from human iPSCs. Stem Cell Rep. 2019;12(6):1380\u20138.","journal-title":"Stem Cell Rep"},{"issue":"8","key":"315_CR48","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nbt.2247","volume":"30","author":"ES Lippmann","year":"2012","unstructured":"Lippmann ES, Azarin SM, Kay JE, Nessler RA, Wilson HK, Al-Ahmad A, Palecek SP, Shusta EV. Derivation of blood\u2013brain barrier endothelial cells from human pluripotent stem cells. Nat Biotechnol. 2012;30(8):783\u201391.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"315_CR49","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41593-018-0242-x","volume":"21","author":"S Hickman","year":"2018","unstructured":"Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci. 2018;21(10):1359\u201369.","journal-title":"Nat Neurosci"},{"issue":"4","key":"315_CR50","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrneurol.2010.17","volume":"6","author":"VH Perry","year":"2010","unstructured":"Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6(4):193\u2013201.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"315_CR51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41583-020-0263-9","volume":"21","author":"AD Greenhalgh","year":"2020","unstructured":"Greenhalgh AD, David S, Bennett FC. Immune cell regulation of glia during CNS injury and disease. Nat Rev Neurosci. 2020;21(3):139\u201352.","journal-title":"Nat Rev Neurosci"},{"issue":"6301","key":"315_CR52","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.aag2590","volume":"353","author":"RM Ransohoff","year":"2016","unstructured":"Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353(6301):777\u201383.","journal-title":"Science"},{"issue":"1","key":"315_CR53","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9(1): 42-020-00221-2.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"315_CR54","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13812-z","volume":"10","author":"K Haruwaka","year":"2019","unstructured":"Haruwaka K, Ikegami A, Tachibana Y, Ohno N, Konishi H, Hashimoto A, Matsumoto M, Kato D, Ono R, Kiyama H, Moorhouse AJ, Nabekura J, Wake H. Dual microglia effects on blood brain barrier permeability induced by systemic inflammation. Nat Commun. 2019;10(1): 5816-019-13812-z.","journal-title":"Nat Commun"},{"issue":"1\u20132","key":"315_CR55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijpharm.2015.12.046","volume":"499","author":"O Gartziandia","year":"2016","unstructured":"Gartziandia O, Egusquiaguirre SP, Bianco J, Pedraz JL, Igartua M, Hernandez RM, Pr\u00e9at V, Beloqui A. Nanoparticle transport across in vitro olfactory cell monolayers. Int J Pharm. 2016;499(1\u20132):81\u20139.","journal-title":"Int J Pharm"},{"key":"315_CR56","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejpb.2015.01.028","volume":"91","author":"SP Egusquiaguirre","year":"2015","unstructured":"Egusquiaguirre SP, Mangu\u00e1n-Garc\u00eda C, Pintado-Berninches L, Iarriccio L, Carbajo D, Albericio F, Royo M, Pedraz JL, Hern\u00e1ndez RM, Perona R, Igartua M. Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: a promising approach for the treatment of defective telomerase disorders. Eur J Pharm Biopharm. 2015;91:91\u2013102.","journal-title":"Eur J Pharm Biopharm"},{"key":"315_CR57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.scr.2016.12.006","volume":"18","author":"E Uhlin","year":"2017","unstructured":"Uhlin E, R\u00f6nnholm H, Day K, Kele M, Tammimies K, B\u00f6lte S, Falk A. Derivation of human iPS cell lines from monozygotic twins in defined and xeno free conditions. Stem Cell Res. 2017;18:22\u20135.","journal-title":"Stem Cell Res"},{"key":"315_CR58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymeth.2015.10.016","volume":"101","author":"MJ Stebbins","year":"2016","unstructured":"Stebbins MJ, Wilson HK, Canfield SG, Qian T, Palecek SP, Shusta EV. Differentiation and characterization of human pluripotent stem cell-derived brain microvascular endothelial cells. Methods. 2016;101:93\u2013102.","journal-title":"Methods"},{"key":"315_CR59","unstructured":"ISO 10993-5 2: Biological evaluation of medical devices-Part 5: Tests for in vitro cytotoxicity (2009). https:\/\/www.iso.org\/standard\/36406.html."},{"issue":"4","key":"315_CR60","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jnutbio.2009.01.012","volume":"21","author":"PY Wang","year":"2010","unstructured":"Wang PY, Chen JJ, Su HM. Docosahexaenoic acid supplementation of primary rat hippocampal neurons attenuates the neurotoxicity induced by aggregated amyloid beta protein(42) and up-regulates cytoskeletal protein expression. J Nutr Biochem. 2010;21(4):345\u201350.","journal-title":"J Nutr Biochem"},{"issue":"9","key":"315_CR61","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jnutbio.2005.02.002","volume":"16","author":"D Cao","year":"2005","unstructured":"Cao D, Xue R, Xu J, Liu Z. Effects of docosahexaenoic acid on the survival and neurite outgrowth of rat cortical neurons in primary cultures. J Nutr Biochem. 2005;16(9):538\u201346.","journal-title":"J Nutr Biochem"},{"key":"315_CR62","first-page":"2","volume":"3","author":"J Ciesler","year":"2013","unstructured":"Ciesler J, Sari Y. Neurotrophic peptides: potential drugs for treatment of amyotrophic lateral sclerosis and Alzheimer\u2019s disease. Open J Neurosci. 2013;3:2.","journal-title":"Open J Neurosci"},{"issue":"5","key":"315_CR63","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.cell.2015.10.067","volume":"163","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and dysfunction of the blood\u2013brain barrier. Cell. 2015;163(5):1064\u201378.","journal-title":"Cell"},{"key":"315_CR64","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","volume":"270","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Peng Z, Seven ES, Leblanc RM. Crossing the blood-brain barrier with nanoparticles. J Control Release. 2018;270:290\u2013303.","journal-title":"J Control Release"},{"key":"315_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cells7040024","author":"Q He","year":"2018","unstructured":"He Q, Liu J, Liang J, Liu X, Li W, Liu Z, Ding Z, Tuo D. Towards improvements for penetrating the blood\u2013brain barrier-recent progress from a material and pharmaceutical perspective. Cells. 2018. https:\/\/doi.org\/10.3390\/cells7040024.","journal-title":"Cells"},{"key":"315_CR66","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2020.103533","volume":"107","author":"L Delsing","year":"2020","unstructured":"Delsing L, Herland A, Falk A, Hicks R, Synnergren J, Zetterberg H. Models of the blood\u2013brain barrier using iPSC-derived cells. Mol Cell Neurosci. 2020;107: 103533.","journal-title":"Mol Cell Neurosci"},{"key":"315_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10588-0","author":"TE Park","year":"2019","unstructured":"Park TE, Mustafaoglu N, Herland A, Hasselkus R, Mannix R, FitzGerald EA, Prantil-Baun R, Watters A, Henry O, Benz M, Sanchez H, McCrea HJ, Goumnerova LC, Song HW, Palecek SP, Shusta E, Ingber DE. Hypoxia-enhanced blood\u2013brain barrier chip recapitulates human barrier function and shuttling of drugs and antibodies. Nat Commun. 2019. https:\/\/doi.org\/10.1038\/s41467-019-10588-0.","journal-title":"Nat Commun"},{"issue":"32","key":"315_CR68","volume":"17","author":"I Matthiesen","year":"2021","unstructured":"Matthiesen I, Voulgaris D, Nikolakopoulou P, Winkler TE, Herland A. Continuous monitoring reveals protective effects of N-acetylcysteine amide on an isogenic microphysiological model of the neurovascular unit. Small. 2021;17(32): e2101785.","journal-title":"Small"},{"issue":"12","key":"315_CR69","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1021\/acs.molpharmaceut.6b00818","volume":"13","author":"JL Mantle","year":"2016","unstructured":"Mantle JL, Min L, Lee KH. Minimum transendothelial electrical resistance thresholds for the study of small and large molecule drug transport in a human in vitro blood\u2013brain barrier model. Mol Pharm. 2016;13(12):4191\u20138.","journal-title":"Mol Pharm"},{"key":"315_CR70","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.2147\/IJN.S215941","volume":"14","author":"RB Dos Santos","year":"2019","unstructured":"Dos Santos RB, Lakkadwala S, Kanekiyo T, Singh J. Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties. Int J Nanomed. 2019;14:6497\u2013517.","journal-title":"Int J Nanomed"},{"issue":"1","key":"315_CR71","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.biomaterials.2013.09.094","volume":"35","author":"X Jiang","year":"2014","unstructured":"Jiang X, Xin H, Ren Q, Gu J, Zhu L, Du F, Feng C, Xie Y, Sha X, Fang X. Nanoparticles of 2-deoxy-d-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials. 2014;35(1):518\u201329.","journal-title":"Biomaterials"},{"key":"315_CR72","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejpb.2019.06.004","volume":"142","author":"A Cox","year":"2019","unstructured":"Cox A, Vinciguerra D, Re F, Magro RD, Mura S, Masserini M, Couvreur P, Nicolas J. Protein-functionalized nanoparticles derived from end-functional polymers and polymer prodrugs for crossing the blood-brain barrier. Eur J Pharm Biopharm. 2019;142:70\u201382.","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"315_CR73","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.molpharmaceut.9b01117","volume":"17","author":"MM Lubtow","year":"2020","unstructured":"Lubtow MM, Oerter S, Quader S, Jeanclos E, Cubukova A, Krafft M, Haider MS, Schulte C, Meier L, Rist M, Sampetrean O, Kinoh H, Gohla A, Kataoka K, Appelt-Menzel A, Luxenhofer R. In vitro blood-brain barrier permeability and cytotoxicity of an atorvastatin-loaded nanoformulation against glioblastoma in 2D and 3D models. Mol Pharm. 2020;17(6):1835\u201347.","journal-title":"Mol Pharm"},{"issue":"41","key":"315_CR74","doi-asserted-by":"crossref","first-page":"35613","DOI":"10.1021\/acsami.7b11615","volume":"9","author":"X Hao","year":"2017","unstructured":"Hao X, Li Q, Guo J, Ren X, Feng Y, Shi C, Zhang W. Multifunctional gene carriers with enhanced specific penetration and nucleus accumulation to promote neovascularization of HUVECs in vivo. ACS Appl Mater Interfaces. 2017;9(41):35613\u201327.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"315_CR75","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1570159X11311020006","volume":"11","author":"LL Zou","year":"2013","unstructured":"Zou LL, Ma JL, Wang T, Yang TB, Liu CB. Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system. Curr Neuropharmacol. 2013;11(2):197\u2013208.","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"315_CR76","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00232-016-9940-z","volume":"250","author":"L Zou","year":"2017","unstructured":"Zou L, Peng Q, Wang P, Zhou B. Progress in research and application of HIV-1 TAT-derived cell-penetrating peptide. J Membr Biol. 2017;250(2):115\u201322.","journal-title":"J Membr Biol"},{"issue":"2","key":"315_CR77","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejpb.2013.01.029","volume":"84","author":"A Beloqui","year":"2013","unstructured":"Beloqui A, Solinis MA, Delgado A, Evora C, del Pozo-Rodriguez A, Rodriguez-Gascon A. Biodistribution of nanostructured lipid carriers (NLCs) after intravenous administration to rats: influence of technological factors. Eur J Pharm Biopharm. 2013;84(2):309\u201314.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"315_CR78","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-018-1288-0","volume":"15","author":"C Dello Russo","year":"2018","unstructured":"Dello Russo C, Cappoli N, Coletta I, Mezzogori D, Paciello F, Pozzoli G, Navarra P, Battaglia A. The human microglial HMC3 cell line: where do we stand? A systematic literature review. J Neuroinflamm. 2018;15(1): 259-018-1288-0.","journal-title":"J Neuroinflamm"},{"key":"315_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-121","author":"W Sheng","year":"2011","unstructured":"Sheng W, Zong Y, Mohammad A, Ajit D, Cui J, Han D, Hamilton JL, Simonyi A, Sun AY, Gu Z, Hong JS, Weisman GA, Sun GY. Pro-inflammatory cytokines and lipopolysaccharide induce changes in cell morphology, and upregulation of ERK1\/2, iNOS and sPLA(2)-IIA expression in astrocytes and microglia. J Neuroinflamm. 2011. https:\/\/doi.org\/10.1186\/1742-2094-8-121.","journal-title":"J Neuroinflamm"},{"key":"315_CR80","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-015-0332-6","volume":"12","author":"IC Hoogland","year":"2015","unstructured":"Hoogland IC, Houbolt C, van Westerloo DJ, van Gool WA, van de Beek D. Systemic inflammation and microglial activation: systematic review of animal experiments. J Neuroinflamm. 2015;12: 114-015-0332-6.","journal-title":"J Neuroinflamm"},{"issue":"1","key":"315_CR81","doi-asserted-by":"crossref","first-page":"170-017-0939-x","DOI":"10.1186\/s12974-017-0939-x","volume":"14","author":"C Fourrier","year":"2017","unstructured":"Fourrier C, Remus-Borel J, Greenhalgh AD, Guichardant M, Bernoud-Hubac N, Lagarde M, Joffre C, Laye S. Docosahexaenoic acid-containing choline phospholipid modulates LPS-induced neuroinflammation in vivo and in microglia in vitro. J Neuroinflamm. 2017;14(1):170-017-0939\u2013x.","journal-title":"J Neuroinflamm"},{"issue":"1","key":"315_CR82","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jnr.20615","volume":"82","author":"C Lindberg","year":"2005","unstructured":"Lindberg C, Crisby M, Winblad B, Schultzberg M. Effects of statins on microglia. J Neurosci Res. 2005;82(1):10\u20139.","journal-title":"J Neurosci Res"},{"key":"315_CR83","first-page":"302","volume":"17","author":"H Li","year":"2018","unstructured":"Li H, Zhang X, Chen M, Chen J, Gao T, Yao S. Dexmedetomidine inhibits inflammation in microglia cells under stimulation of LPS and ATP by c-Fos\/NLRP3\/caspase-1 cascades. EXCLI J. 2018;17:302\u201311.","journal-title":"EXCLI J"},{"issue":"5","key":"315_CR84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125419","volume":"10","author":"AR Rajalakshmy","year":"2015","unstructured":"Rajalakshmy AR, Malathi J, Madhavan HN. Hepatitis C virus NS3 mediated microglial inflammation via TLR2\/TLR6 MyD88\/NF-kappaB pathway and toll like receptor ligand treatment furnished immune tolerance. PLoS ONE. 2015;10(5): e0125419.","journal-title":"PLoS ONE"},{"issue":"6","key":"315_CR85","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/jnc.12933","volume":"131","author":"VS Jadhav","year":"2014","unstructured":"Jadhav VS, Krause KH, Singh SK. HIV-1 Tat C modulates NOX2 and NOX4 expressions through miR-17 in a human microglial cell line. J Neurochem. 2014;131(6):803\u201315.","journal-title":"J Neurochem"},{"issue":"1","key":"315_CR86","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/pr.117.014092","volume":"70","author":"S Laye","year":"2018","unstructured":"Laye S, Nadjar A, Joffre C, Bazinet RP. Anti-inflammatory effects of omega-3 fatty acids in the brain: physiological mechanisms and relevance to pharmacology. Pharmacol Rev. 2018;70(1):12\u201338.","journal-title":"Pharmacol Rev"},{"issue":"4","key":"315_CR87","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3233\/JAD-130131","volume":"35","author":"E Hjorth","year":"2013","unstructured":"Hjorth E, Zhu M, Toro VC, Vedin I, Palmblad J, Cederholm T, Freund-Levi Y, Faxen-Irving G, Wahlund LO, Basun H, Eriksdotter M, Schultzberg M. Omega-3 fatty acids enhance phagocytosis of Alzheimer\u2019s disease-related amyloid-beta42 by human microglia and decrease inflammatory markers. J Alzheimers Dis. 2013;35(4):697\u2013713.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"315_CR88","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jnc.14108","volume":"142","author":"Z Xu","year":"2017","unstructured":"Xu Z, Han K, Chen J, Wang C, Dong Y, Yu M, Bai R, Huang C, Hou L. Vascular endothelial growth factor is neuroprotective against ischemic brain injury by inhibiting scavenger receptor A expression on microglia. J Neurochem. 2017;142(5):700\u20139.","journal-title":"J Neurochem"},{"issue":"3","key":"315_CR89","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.nbd.2012.04.014","volume":"47","author":"SM Rocha","year":"2012","unstructured":"Rocha SM, Cristov\u00e3o AC, Campos FL, Fonseca CP, Baltazar G. Astrocyte-derived GDNF is a potent inhibitor of microglial activation. Neurobiol Dis. 2012;47(3):407\u201315.","journal-title":"Neurobiol Dis"},{"issue":"7","key":"315_CR90","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1253\/circj.CJ-16-0423","volume":"80","author":"ZS Katusic","year":"2016","unstructured":"Katusic ZS, Austin SA. Neurovascular protective function of endothelial nitric oxide\u2014recent advances. Circ J. 2016;80(7):1499\u2013503.","journal-title":"Circ J"},{"issue":"3","key":"315_CR91","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.neulet.2007.11.051","volume":"431","author":"T Tanaka","year":"2008","unstructured":"Tanaka T, Oh-hashi K, Shitara H, Hirata Y, Kiuchi K. NF-\u03baB independent signaling pathway is responsible for LPS-induced GDNF gene expression in primary rat glial cultures. Neurosci Lett. 2008;431(3):262\u20137.","journal-title":"Neurosci Lett"},{"issue":"2","key":"315_CR92","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12975-012-0213-6","volume":"4","author":"JM Bain","year":"2013","unstructured":"Bain JM, Moore L, Ren Z, Simonishvili S, Levison SW. Vascular endothelial growth factors A and C are induced in the SVZ following neonatal hypoxia-ischemia and exert different effects on neonatal glial progenitors. Transl Stroke Res. 2013;4(2):158\u201370.","journal-title":"Transl Stroke Res"},{"issue":"3","key":"315_CR93","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/jcb.20646","volume":"97","author":"YP Chang","year":"2006","unstructured":"Chang YP, Fang KM, Lee TI, Tzeng SF. Regulation of microglial activities by glial cell line derived neurotrophic factor. J Cell Biochem. 2006;97(3):501\u201311.","journal-title":"J Cell Biochem"},{"key":"315_CR94","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.neuropharm.2013.11.004","volume":"79","author":"M Sandberg","year":"2014","unstructured":"Sandberg M, Patil J, D\u2019Angelo B, Weber SG, Mallard C. NRF2-regulation in brain health and disease: Implication of cerebral inflammation. Neuropharmacology. 2014;79:298\u2013306.","journal-title":"Neuropharmacology"},{"key":"315_CR95","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.nbd.2018.10.001","volume":"121","author":"S Hernando","year":"2019","unstructured":"Hernando S, Requejo C, Herran E, Ruiz-Ortega JA, Morera-Herreras T, Lafuente JV, Ugedo L, Gainza E, Pedraz JL, Igartua M, Hernandez RM. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson\u2019s disease: the role of glia and NRf2 regulation. Neurobiol Dis. 2019;121:252\u201362.","journal-title":"Neurobiol Dis"},{"issue":"7","key":"315_CR96","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1002\/jcb.26712","volume":"119","author":"P Yue","year":"2018","unstructured":"Yue P, Gao L, Wang X, Ding X, Teng J. Pretreatment of glial cell-derived neurotrophic factor and geranylgeranylacetone ameliorates brain injury in Parkinson\u2019s disease by its anti-apoptotic and anti-oxidative property. J Cell Biochem. 2018;119(7):5491\u2013502.","journal-title":"J Cell Biochem"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-022-00315-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-022-00315-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-022-00315-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T01:04:08Z","timestamp":1647479048000},"score":1,"resource":{"primary":{"URL":"https:\/\/fluidsbarrierscns.biomedcentral.com\/articles\/10.1186\/s12987-022-00315-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["315"],"URL":"https:\/\/doi.org\/10.1186\/s12987-022-00315-1","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"11 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}